1|Page
NR 565 FINAL EXAM (2026) |
CHAMBERLAIN ADVANCED
PHARMACOLOGY – PRACTICE
QUESTIONS 1–100 AND ANSWERS
UPDATED 2026/2027 | DETAILED
RATIONALES
Introduction
The NR 565 Final Exam is associated with advanced pharmacology study in graduate nursing
education. Students preparing for an advanced pharmacology assessment need to demonstrate
more than memorization: they must apply pharmacokinetic and pharmacodynamic principles,
select appropriate medications, recognize contraindications, anticipate adverse effects, evaluate
drug interactions, and develop safe monitoring plans. These skills are essential for advanced
practice nurses who make or contribute to prescribing decisions.
This practice bank is designed for graduate nursing students reviewing major advanced
pharmacology concepts. It uses challenging clinical scenarios, four-option multiple-choice
questions, and explanations that discuss why the best answer is appropriate and why the
alternatives are less suitable. Topics include prescribing principles, cardiovascular medications,
endocrine and respiratory therapies, antimicrobials, psychiatric medications, pain management,
and patient-specific considerations such as pregnancy, kidney function, and older age.
Use the questions to identify knowledge gaps, explain your reasoning aloud, and revisit the
underlying pharmacology when you miss an item. The questions are original study exercises, not
a verified copy of Chamberlain’s exam or a guarantee of a particular grade. Confirm your
course’s current objectives and assigned materials to ensure your preparation matches the official
assessment.
Content area overview
The exact current NR 565 exam blueprint was not supplied, so the distribution below is a
suggested review plan, not an official Chamberlain weighting.
Suggested
Content area Questions Key topics
weight
Pharmacokinetics,
Prescribing principles and
1–10 pharmacodynamics, safety, 10%
pharmacology
interactions
,2|Page
Hypertension, heart failure,
Cardiovascular medications 11–22 12%
anticoagulants, dyslipidemia
Diabetes, thyroid disorders,
Endocrine medications 23–32 10%
corticosteroids
Antibiotics, resistance, renal dosing,
Antimicrobials 33–44 12%
monitoring
Asthma, COPD, inhalers, adverse
Respiratory medications 45–52 8%
effects
Antidepressants, antipsychotics, mood
Psychiatric medications 53–62 10%
stabilizers
Pain and neurologic Analgesics, opioids, seizure
63–72 10%
medications medications
Gastrointestinal medications 73–78 Reflux, ulcer disease, nausea 6%
Reproductive health and Contraception, pregnancy, older
79–86 8%
special populations adults, pediatrics
Medication safety and clinical Monitoring, interactions, patient
87–100 14%
decision-making education
QUESTIONS 1–100
Prescribing principles and pharmacology
Q1. A patient with chronic kidney disease is prescribed a medication that is primarily eliminated
unchanged by the kidneys. After several weeks, the patient develops confusion and ataxia despite
taking the prescribed dose. Which pharmacologic principle best explains this presentation?
A) Increased first-pass metabolism B) Reduced renal clearance causing drug accumulation C)
Increased protein binding that accelerates elimination D) Reduced bioavailability caused by
kidney disease
Rationale: B is correct because impaired renal clearance can increase the drug’s half-life and
serum concentration, causing toxicity even at a standard dose. A concerns hepatic metabolism
and does not explain reduced renal elimination. C is incorrect because greater protein binding
generally reduces the free fraction initially and does not explain this classic accumulation
mechanism. D concerns absorption and is not the primary issue.
Q2. A patient taking warfarin begins a medication that strongly inhibits CYP2C9. The INR rises
substantially. What is the best explanation?
A) The new medication increases renal excretion of warfarin B) Warfarin absorption is
completely blocked C) Inhibition of warfarin metabolism increases anticoagulant exposure D)
The interaction decreases warfarin’s pharmacodynamic effect
, 3|Page
Rationale: C is correct because CYP2C9 inhibition can reduce metabolism of the more potent S-
warfarin, increasing anticoagulant effect and bleeding risk. A does not describe the principal
pathway. B would tend to reduce, not increase, exposure. D contradicts the observed INR
elevation.
Q3. A patient experiences anaphylaxis shortly after taking a medication for the first time that
day. Which statement about the reaction is most accurate?
A) It must be dose-dependent toxicity B) It proves the medication has a narrow therapeutic index
C) It is necessarily caused by accumulation over time D) It is a potentially life-threatening
hypersensitivity reaction requiring immediate treatment
Rationale: D is correct. Anaphylaxis requires prompt emergency management, including
intramuscular epinephrine when indicated. A describes predictable dose-related toxicity, not
anaphylaxis. B is unrelated to whether a drug has a narrow therapeutic index. C is incorrect
because severe hypersensitivity can occur rapidly and does not require drug accumulation.
Q4. A patient takes a medication with a narrow therapeutic index. Which change most strongly
supports closer serum-level monitoring?
A) The patient switches to a different colored tablet from the same manufacturer B) The patient
develops significant renal impairment C) The patient reports preferring morning dosing D) The
patient begins taking the medication with water
Rationale: B is correct because renal impairment may substantially alter drug clearance and raise
concentrations. A tablet’s color alone does not establish a pharmacokinetic change. C may matter
for adherence but does not inherently change drug exposure. D is generally an appropriate
administration method and is not, by itself, a reason for intensive monitoring.
Q5. A patient reports taking an extended-release tablet by crushing it because swallowing pills is
difficult. What is the most appropriate response?
A) Continue crushing it and divide the dose throughout the day B) Mix the crushed tablet into a
hot drink C) Verify the formulation and switch to a suitable alternative if crushing is unsafe D)
Double the next dose to compensate for medication lost during crushing
Rationale: C is correct because crushing some extended-release formulations can release the drug
too rapidly and cause toxicity. A and B may compromise the release mechanism. D risks
overdose and is never an appropriate response to uncertainty about the administered dose.
Q6. A patient’s medication has a half-life of approximately 12 hours and follows first-order
elimination. Assuming stable kinetics and regular dosing, approximately how long does it
usually take to approach steady state?
A) 12 hours B) 24 hours C) About 2–3 days D) 10–14 days
NR 565 FINAL EXAM (2026) |
CHAMBERLAIN ADVANCED
PHARMACOLOGY – PRACTICE
QUESTIONS 1–100 AND ANSWERS
UPDATED 2026/2027 | DETAILED
RATIONALES
Introduction
The NR 565 Final Exam is associated with advanced pharmacology study in graduate nursing
education. Students preparing for an advanced pharmacology assessment need to demonstrate
more than memorization: they must apply pharmacokinetic and pharmacodynamic principles,
select appropriate medications, recognize contraindications, anticipate adverse effects, evaluate
drug interactions, and develop safe monitoring plans. These skills are essential for advanced
practice nurses who make or contribute to prescribing decisions.
This practice bank is designed for graduate nursing students reviewing major advanced
pharmacology concepts. It uses challenging clinical scenarios, four-option multiple-choice
questions, and explanations that discuss why the best answer is appropriate and why the
alternatives are less suitable. Topics include prescribing principles, cardiovascular medications,
endocrine and respiratory therapies, antimicrobials, psychiatric medications, pain management,
and patient-specific considerations such as pregnancy, kidney function, and older age.
Use the questions to identify knowledge gaps, explain your reasoning aloud, and revisit the
underlying pharmacology when you miss an item. The questions are original study exercises, not
a verified copy of Chamberlain’s exam or a guarantee of a particular grade. Confirm your
course’s current objectives and assigned materials to ensure your preparation matches the official
assessment.
Content area overview
The exact current NR 565 exam blueprint was not supplied, so the distribution below is a
suggested review plan, not an official Chamberlain weighting.
Suggested
Content area Questions Key topics
weight
Pharmacokinetics,
Prescribing principles and
1–10 pharmacodynamics, safety, 10%
pharmacology
interactions
,2|Page
Hypertension, heart failure,
Cardiovascular medications 11–22 12%
anticoagulants, dyslipidemia
Diabetes, thyroid disorders,
Endocrine medications 23–32 10%
corticosteroids
Antibiotics, resistance, renal dosing,
Antimicrobials 33–44 12%
monitoring
Asthma, COPD, inhalers, adverse
Respiratory medications 45–52 8%
effects
Antidepressants, antipsychotics, mood
Psychiatric medications 53–62 10%
stabilizers
Pain and neurologic Analgesics, opioids, seizure
63–72 10%
medications medications
Gastrointestinal medications 73–78 Reflux, ulcer disease, nausea 6%
Reproductive health and Contraception, pregnancy, older
79–86 8%
special populations adults, pediatrics
Medication safety and clinical Monitoring, interactions, patient
87–100 14%
decision-making education
QUESTIONS 1–100
Prescribing principles and pharmacology
Q1. A patient with chronic kidney disease is prescribed a medication that is primarily eliminated
unchanged by the kidneys. After several weeks, the patient develops confusion and ataxia despite
taking the prescribed dose. Which pharmacologic principle best explains this presentation?
A) Increased first-pass metabolism B) Reduced renal clearance causing drug accumulation C)
Increased protein binding that accelerates elimination D) Reduced bioavailability caused by
kidney disease
Rationale: B is correct because impaired renal clearance can increase the drug’s half-life and
serum concentration, causing toxicity even at a standard dose. A concerns hepatic metabolism
and does not explain reduced renal elimination. C is incorrect because greater protein binding
generally reduces the free fraction initially and does not explain this classic accumulation
mechanism. D concerns absorption and is not the primary issue.
Q2. A patient taking warfarin begins a medication that strongly inhibits CYP2C9. The INR rises
substantially. What is the best explanation?
A) The new medication increases renal excretion of warfarin B) Warfarin absorption is
completely blocked C) Inhibition of warfarin metabolism increases anticoagulant exposure D)
The interaction decreases warfarin’s pharmacodynamic effect
, 3|Page
Rationale: C is correct because CYP2C9 inhibition can reduce metabolism of the more potent S-
warfarin, increasing anticoagulant effect and bleeding risk. A does not describe the principal
pathway. B would tend to reduce, not increase, exposure. D contradicts the observed INR
elevation.
Q3. A patient experiences anaphylaxis shortly after taking a medication for the first time that
day. Which statement about the reaction is most accurate?
A) It must be dose-dependent toxicity B) It proves the medication has a narrow therapeutic index
C) It is necessarily caused by accumulation over time D) It is a potentially life-threatening
hypersensitivity reaction requiring immediate treatment
Rationale: D is correct. Anaphylaxis requires prompt emergency management, including
intramuscular epinephrine when indicated. A describes predictable dose-related toxicity, not
anaphylaxis. B is unrelated to whether a drug has a narrow therapeutic index. C is incorrect
because severe hypersensitivity can occur rapidly and does not require drug accumulation.
Q4. A patient takes a medication with a narrow therapeutic index. Which change most strongly
supports closer serum-level monitoring?
A) The patient switches to a different colored tablet from the same manufacturer B) The patient
develops significant renal impairment C) The patient reports preferring morning dosing D) The
patient begins taking the medication with water
Rationale: B is correct because renal impairment may substantially alter drug clearance and raise
concentrations. A tablet’s color alone does not establish a pharmacokinetic change. C may matter
for adherence but does not inherently change drug exposure. D is generally an appropriate
administration method and is not, by itself, a reason for intensive monitoring.
Q5. A patient reports taking an extended-release tablet by crushing it because swallowing pills is
difficult. What is the most appropriate response?
A) Continue crushing it and divide the dose throughout the day B) Mix the crushed tablet into a
hot drink C) Verify the formulation and switch to a suitable alternative if crushing is unsafe D)
Double the next dose to compensate for medication lost during crushing
Rationale: C is correct because crushing some extended-release formulations can release the drug
too rapidly and cause toxicity. A and B may compromise the release mechanism. D risks
overdose and is never an appropriate response to uncertainty about the administered dose.
Q6. A patient’s medication has a half-life of approximately 12 hours and follows first-order
elimination. Assuming stable kinetics and regular dosing, approximately how long does it
usually take to approach steady state?
A) 12 hours B) 24 hours C) About 2–3 days D) 10–14 days
